Istituto Oncologico Del Mediterraneo S.p.A.
- Address
- Via Penninazzo 7, 95029 Viagrande, Italy
Istituto Oncologico Del Mediterraneo S.p.A.
Istituto Oncologico Del Mediterraneo S.p.A. is a specialized oncology research center dedicated to advancing cancer treatment through comprehensive clinical investigation. The institute demonstrates particular expertise in precision medicine approaches, combining targeted therapies with immunotherapy and chemotherapy regimens across multiple cancer types.
- Neuroendocrine tumors, including pulmonary large-cell neuroendocrine carcinoma (LCNEC) and gastroenteropancreatic neuroendocrine tumors (GEP-NETs)
- Colorectal cancer with focus on liquid biopsy and RAS/BRAF mutation analysis
- Breast cancer, particularly hormone receptor-positive, HER2-negative early-stage disease with high recurrence risk
The center is actively engaged in Phase II and Phase III trials evaluating novel therapeutic combinations and biomarker-driven treatment selection. Their research portfolio includes immunotherapy combinations with durvalumab, targeted therapies such as cabozantinib and elacestrant, and personalized approaches using liquid biopsy to guide treatment decisions in metastatic colorectal cancer. The institute's commitment to translational research is evident through integrated molecular profiling and immunohistochemical analyses aimed at identifying predictive and prognostic biomarkers.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 3 by active trials.
lock +2 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 566 other sites in Italy
Therapeutic Area Benchmark — Italy
Select a therapeutic area to compare against other sites in Italy.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Italy
Market Share
Country: Italy
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Istituto Oncologico Del Mediterraneo S.p.A.
lock Showing 1 of 4 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Evaluation of Cabozantinib and Lanreotide Combination in Gastroenteropancreatic and Thoracic Neuroendocrine Tumors: A Phase II Clinical Trial | Fondazione IRCCS Istituto Nazionale Dei Tumori | Phase II | Recruiting | Jun 2020 | — |
IMP list
lock Showing 1 of 15 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Anastrozole | 1 | Unknown | 2025-03-24 | 2025-03-24 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.